Benzyl Benzoate
| 證據等級: L5 | 預測適應症: 0 個 |
目錄
- Benzyl Benzoate
- Benzyl Benzoate (DB00676): Drug Repurposing Assessment — Insufficient Data for Active Prediction
Benzyl Benzoate (DB00676): Drug Repurposing Assessment — Insufficient Data for Active Prediction
One-Sentence Summary
Benzyl Benzoate is a well-established topical antiparasitic agent with recognised use in the treatment of scabies and pediculosis (lice infestation). The current Evidence Pack contains no TxGNN-generated repurposing predictions for this drug, and Benzyl Benzoate holds no SAHPRA registrations in South Africa. A complete repurposing evaluation cannot proceed until two blocking data gaps — regulatory safety information and mechanism of action — are resolved and the prediction pipeline is re-run.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally recorded in this Evidence Pack |
| Predicted New Indication | None available |
| TxGNN Prediction Score | Not available |
| Evidence Level | Not applicable — no predictions generated |
| South Africa Market Status | Not marketed |
| Number of SAHPRA Registrations | 0 |
| Recommended Decision | Hold |
Safety Considerations
No safety data — including key warnings, contraindications, or drug interaction records — was available in this Evidence Pack. As Benzyl Benzoate holds no current SAHPRA registration, there is no locally approved Professional Information (PI) to reference. For interim safety guidance, consult the WHO Model Formulary, international product labelling, or DrugBank entry DB00676. Any adverse reactions observed in clinical practice should still be reported to SAHPRA through the MedSafety reporting system.
Conclusion and Next Steps
Decision: Hold
Rationale: The Evidence Pack for Benzyl Benzoate is incomplete at a foundational level: the TxGNN pipeline returned no repurposing candidates, no mechanism of action is available to support biological plausibility analysis, and the drug carries no SAHPRA registration history. There is no evidence base on which to build a repurposing recommendation at this stage.
To proceed, the following is needed:
- Resolve DG001 (Blocking): Obtain regulatory safety data — warnings and contraindications — from an authoritative source (e.g., WHO Model Formulary, EMA public assessment reports, or DrugBank DB00676). Without this, no safety screening can be completed.
- Resolve DG002 (High): Retrieve the complete mechanism of action from DrugBank (DB00676) to enable mechanistic plausibility analysis for any predicted indication.
- Re-run TxGNN predictions: Once the above gaps are resolved, re-submit Benzyl Benzoate to the TxGNN pipeline to generate repurposing candidates with associated scores and disease targets.
- Assess regulatory pathway: Determine whether Benzyl Benzoate has been registered in comparable jurisdictions (e.g., FDA, EMA, UK MHRA) and whether a Section 21 authorisation or full SAHPRA registration would be required if a repurposing indication is identified.
- Confirm market availability: Verify whether any Benzyl Benzoate-containing product (branded or generic) is currently available in South Africa through the SAHPRA online register before assuming the drug is inaccessible to patients.
Disclaimer: This report is for research reference only and does not constitute medical advice. Any drug repurposing candidate identified by TxGNN requires clinical validation before therapeutic application. Report adverse drug reactions to SAHPRA.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.